跳至主要内容
临床试验/ACTRN12614000617662
ACTRN12614000617662尚未招募未知

A randomized, double blind study testing the effect of indacaterol on exhaled and circulatory biomarkers of Chronic Obstructive Pulmonary Disease (COPD).

ung Institute of Western Australia0 个研究点目标入组 200 人开始时间: 2014年6月11日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
50 Years 至 70 Years(—)
性别
All

入选标准

  • The people eligible for the study are patients with 1)COPD. based on the criteria described below. 2) Healthy controls with no COPD and within the same age range as subjects with COPD.
  • 1.GOLD Criteria for severity of COPD
  • a.Mild – FEV1/FVC< 70%, FEV1< 80%
  • b.Moderate – FEV1/FVC< 70%, FEV1 50-80%
  • 2.COPD chronic bronchitis or Emphysema
  • 3.Age – 50-70 years
  • 4.males and females

排除标准

  • 1.Present smokers
  • 2.Severe CCF
  • 3.Liver, renal failure
  • 4.Diabetes
  • 5.On immunosuppressive drugs
  • 6.Auto-immune conditions such RA
  • 7.Vascular disease – Scleroderma , SLE
  • 8.Any history of asthma
  • 9.Exacerbations in the last 6 weeks
  • 10.Women of childbearing potential not using the contraception method(s) specified in this study (specify), as well as women who are breastfeeding
  • 11.Known sensitivity to study drug(s) or class of study drug(s)
  • 12.Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required)

研究者

发起方
ung Institute of Western Australia

相似试验